Course InformationTherapautic Area: Cardiology
Credit(s): 2.00 AMA PRA Category 1 Credit(s)™
Activity Dates: May 30, 2017 - May 29, 2018
This educational content was derived from the American College of Physicians Internal Medicine Meeting 2017 in San Diego, California. This activity will focus on optimized treatment plans for patients with dyslipidemia in the era of PCSK9 inhibitor therapeutics. LDL-C has been identified as an important therapeutic target to prevent the progression of atherosclerotic disease, however only 1 out of every 3 adults with high LDL-C has the condition under control. Expert faculty on this panel will discuss the science of PCSK9 inhibitors and aid physicians in the best practices to get their patients at LDL-C target.
Cardiologists, internists, primary care physicians, and other healthcare professionals responsible for the diagnosis, treatment or management of patients with dyslipidemia.
- Discuss the science of PCSK9 inhibitor therapeutics and the current ACC/AHA/NLA guidelines for patients with dyslipidemia.
- Analyze clinical trial data for PCSK9 inhibitor therapeutics.
- Integrate personalized treatment plans for patients with statin intolerance, familial hypercholesterolemia, and dyslipidemia patients not at LDL-C goal.
James A. Underberg, MD
Clinical Assistant Professor of Medicine
NYU School of Medicine
NYU Center for Prevention of Cardiovascular Disease
Director Bellevue Hospital Lipid Clinic
President-Elect National Lipid Association
New York, New York
Peter H. Jones, MD
Associate Professor Medicine
Center for Cardiovascular Disease Prevention
Co-Director, Lipid Metabolism and Atherosclerosis Clinic
Baylor College of Medicine
Houston, TX, US
This activity is expired for CE Credit
This CME activity has been supported by an independent educational grant from Amgen Inc.